

# Competitor Analysis: Emerging Diabetes Drugs

<https://marketpublishers.com/r/C482A7D2124EN.html>

Date: April 2011

Pages: 104

Price: US\$ 870.00 (Single User License)

ID: C482A7D2124EN

## Abstracts

### Product description

The present Competitive Intelligence Report about Emerging Diabetes Drugs provides a competitor evaluation in the field of novel molecules against a series of novel targets being developed for treatment of type 1 or 2 diabetes as of April 2011. Pharmacologic approaches include SGLT inhibitors, glucokinase activators, 11beta-HSD1 inhibitors and many others. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

The report includes a compilation of currently active projects in research and development of novel molecules for treatment of type 1 and 2 diabetes. In addition, the report lists company-specific R&D pipelines of emerging diabetes drugs in R&D. Competitor projects are listed in a tabular format providing information on:

Drug Codes,

Target / Mechanism of Action,

Class of Compound,

Company,

Product Category,

Indication,

R&D Stage and

additional comments with a hyperlink leading to the source of information.

## **Index**

Sodium-Dependent Glucose Co-Transporter (SGLT) Inhibitors

11beta-Hydroxysteroid Dehydrogenase Type 1 (11beta-HSD1) Inhibitors

Glucokinase Activators (GKA)

Adenosine Monophosphate Activated Protein Kinase (AMPK) Agonists

Sirtuin (SIRT) Activators

Protein tyrosine Phosphatase-1B (PTP-1B) Inhibitors

Glucagon Receptor (GCGR) Antagonists

Glucocorticoid Receptor (GCGR) Antagonists

Novel Insulin Sensitizers

G-Protein Coupled Receptor 119 (GPR119) Agonists

Other Drugs Augmenting GLP-1 Secretion: GPR40, GR120 & TGR5 Agonists

Other Glucometabolic Approaches

Acyl-CoA:Diacylglycerol Acyltransferase1 (DGAT1) Inhibitors

Other Metabolic Approaches

FGF-21-Receptor Agonists

Anti-Inflammatory Approaches

Induction of Immune Tolerance

Pancreatic Beta Cell Protection & Regeneration

Pancreatic Islet Cell Transplantation

Various Antidiabetic Approaches

## **Corporate Emerging Diabetes Drugs R&D Pipelines**

7TM Pharma

Abbott

AdiStem

Advinus Therapeutics

Alize Pharma

ALLOZYNE

Ambrx

Amgen

Amylin Pharmaceuticals

Andromeda

Arena Pharmaceuticals

Array BioPharma

Astellas Pharma

AstraZeneca

Bayhill Therapeutics

Betagenon

BHV Pharma

Biocon

Boehringer Ingelheim

Bristol-Myers Squibb (BMS)

Catabasis Pharmaceuticals

Cellonis Biotechnologies

ChemoCentryx

Columbia University Medical Center

Connexios Life Sciences

Cortendo

CureDM Group

Cyclacel

Cytos Biotechnology

Daiichi Sankyo

Dainippon Sumitomo Pharma

Debiopharm

DiaKine Therapeutics

Diamedica

Diamyd Medical

Eli Lilly

Ensemble Discovery

Evotec

Exsulin

Forest Laboratories

Genzyme

Geron Corp

GlaxoSmithKline (GSK)

Helsinn

High Point Pharmaceuticals

Immunocore

Incyte

Inovio

Intercept Pharmaceuticals

Ipsen

ISIS Pharmaceuticals

Japan Tobacco

Johnson & Johnson (J&J)

Kalypsys

Karo Bio

Kotobuki

Les Laboratoires Servier (Servier)

Lexicon Pharmaceuticals

LG Life Science

Ligand Pharmaceuticals

Living Cell Technologies (LCT)

MacroGenics

MedImmune

Melior Discovery

Mesoblast

Metabolex

Merck & Co.

Mercury Therapeutics

Microslet

Mitsubishi Tanabe Pharma

Neurocrine Biosciences

National Institutes of Health (NIH)

Novartis

NovImmune

Omni Bio Pharmaceutical

Ortho-McNeil-Janssen Pharmaceuticals (OMJPI)

Ortho McNeil (J&J)

Osiris therapeutics

Pfizer

PharmaFrontier

Pinnacle

Piramal Life Sciences

Poxel

Rigel Pharmaceuticals

Roche

Sanofi-Aventis

S2 Therapeutics

Santarus

Sanwa Kagaku Kenkyusho

Sirona Biochem

Takeda Pharmaceutical

Targacept

Teva Pharmaceutical Industries

Theracos

Tolera Therapeutics

Tolerx

TransTech Pharma

VeroScience

Versartis

VIA Pharmaceuticals

ViaCyte

Vitae Pharmaceuticals

Wellstat Therapeutics

XOMA

Yuhan Co.

Zydus Cadila

### **About Competitor Analysis Series:**

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.



## I would like to order

Product name: Competitor Analysis: Emerging Diabetes Drugs

Product link: <https://marketpublishers.com/r/C482A7D2124EN.html>

Price: US\$ 870.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C482A7D2124EN.html>